Hyku Biosciences
hykubiosciences.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
14
US Form 5500 (plan participants) · Dec 2024
Backers
1
Novartis Venture Fund
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Dec 2025 | $6.6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | HYKU BIOSCIENCES INC. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kleem ChaudharyExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Novartis Venture Fund Similar startupsby what they do, their industry and backers
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
Protein Splicing to Develop the Next Generation of Genetic Medicines.
Sidewinder Therapeutics is pioneering the next generation of large molecule precision therapeutics. We aim to deliver new life-saving…
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting…
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…
News
Covalent drugs go from fringe field to fashionable endeavor
Designing molecules that make bonds with their biological targets is in vogue
Read more
Report
Hyku Biosciences Launches With $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery
Read more
Report
The emerging role of mass spectrometry-based proteomics in drug discovery
Proteins are the main targets of most drugs; however, system-wide methods to monitor protein activity and function are still underused in drug discovery. Novel biochemical approaches, in combination with recent developments in mass spectrometry-based prot
Read more
Report
People
Kleem Chaudhary
Executive Officer, Director
John Gustofson
Director
Laura Brass
Director
Laura Tadvalkar
Director
Matthias Van Woensel
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Burlington
United States
HQ
Contact Us
5 Burlington Woods Dr, Suite 103 A, Burlington, MA 01803
Lexington
United States
Regional office
1055 Waltham Street, 3rd Floor Lexington, MA, 02421 United States
Financials
Total raised
$6.6M
Latest round
Debt Financing
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Debt Financing | 2025 | $6.6M | Details |